A clinical study to find out the effect of Hrudbasti a procedure in which oil is applied over heart region along with intake of Ayurvedic formulation in the treatment of Heart Failure.

A Single arm clinical study to evaluate the efficacy of Hrudbasti and Ayurvedic formulation as add on therapy in the management of Congestive Heart Failure with low ejection fraction. - nil

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059255

Enrollment

Registered

2023-10-30

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I509- Heart failure, unspecified Health Condition 2: I509- Heart failure, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1)Known case of - Congestive Heart Failure on Standard Care Treatment with LVEF between 25–55% on a standard two dimensional-Echocardiogram (2D-ECHO) test. 2)Congestive Heart Failure (New York Heart Association, NYHA Class I–III). 3)Class I - No symptoms and no limitation in ordinary physical activity, e.g., shortness of breath when walking, climbing stairs etc. 4)Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. 5)Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20—100m). Comfortable only at rest.

Exclusion criteria

Exclusion criteria: 1)With a 10-year fatal cardiovascular disease risk SCORE 2)Acute myocardial infarction. 3)Unstable Angina. 4)Evidence of any acute metabolic, vascular, infective complications. 5)Known abnormal Liver Function Tests (LFT), Renal Function Tests (RFT) 6)Pregnant and lactating mother. 7)Known history of hemorrhagic stroke. 8)Any other chronic diseases.

Design outcomes

Primary

Measure	Time frame
Changes in Ejection fraction (LVEF%) in 2DEcho.Timepoint: at baseline and after 1 month	—

Secondary

Measure	Time frame
Patient showing relief from clinical signs and symptoms of CHF.Timepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Pallavi Namdeo Mane

Dr D. Y. Ayurved college and research center pimpri, pune, Professor

drdgdipankar@gmail.com09822279321

Outcome results